Species Human Entrez 943 | Human Mouse Ensembl ENSG00000120949 | |
Aliases TNFRSF8, CD30, D1S166E, Ki-1, tumor necrosis factor receptor superfamily member 8 External IDs OMIM: 153243 MGI: 99908 HomoloGene: 949 GeneCards: TNFRSF8 | ||
CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.
Contents
How to enter hidden service menu opel astra h cd30 tid triple information display vauxhall
Function
This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
Clinical significance
CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors. CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.
Cancer treatment
CD30 is the target of the FDA approved therapeutic brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:
- Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
- HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
- Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen
Interactions
CD30 has been shown to interact with TRAF5, TRAF1, TRAF2 and TRAF3.